Replies to post #257315 on Anavex Life Sciences Corp (AVXL)

[rayovacAAA]

NTRP RELEASED THEIR "BAD NEWS" ON 9 SEPTEMBER 2019, NOT 5 SEPTEMBER.

It appears they got the data about July 15 and released the bad news on September 5.

https://neurotrope.com/neurotrope-announces-top-line-results-from-confirmatory-phase-2-study-of-bryostatin-1-in-moderate-to-severe-alzheimers-disease/

NEW YORK, Sept. 9, 2019 /PRNewswire/ — Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), today announced that its confirmatory Phase 2 study of Bryostatin-1 in moderate to severe AD did not achieve statistical significance on the primary endpoint, which was change from baseline to Week 13 in the Severe Impairment Battery (SIB) total score.

[Investor2014]

Agree. It seems absurd not to take the time run the pre-specified subgroups KEM Analysis before releasing results. As I understand the Anavex Precision Medicine approach is all about proving the data driven biomarker hypothesis from the P2a AD data.

If that hypothesis proves out strongly (stat sig) in the current trials I consider that a great success, which significantly increases the chances of approval from pivotal trials with the right medicine for the right patients.

NTRP and BIIB ran posthoc subgroup analysis not to be compared with pre-specified analysis.